MedTrace Logo

The iLet Experience Study

NCT06891898 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1875

Last updated 2025-03-24

No results posted yet for this study

Summary

A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.

Conditions

Interventions

DEVICE

iLet Dosing Decision Software

Interoperable alternate glycemic controller

Sponsors & Collaborators

  • The Scripps Research Institute

    collaborator OTHER

  • Beta Bionics, Inc.

    lead INDUSTRY

Principal Investigators

  • Steven J Russell, MD, PhD · Beta Bionics

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06891898 on ClinicalTrials.gov